Background: Tuberculosis is still a major health problem worldwide. It is estimated that about one-third of the world's population is infected with mycobacterium tuberculosis. Whilepulmonary tuberculosis is most common presentation; extrapulmonary tuberculosis is also an important clinical problem. CBNAAT is cartridge based nucleic acid amplification test with a well-established role in the diagnosis of pulmonary tuberculosis (PTB). We determined the effectiveness of CBNAAT in the diagnosis of extrapulmonary tuberculosis (EPTB) cases in comparison to AFB smear.Methods: Retrospective study of suspected extrapulmonary tuberculosis patients in a tertiary care centre of the study area was conducted. The study period was from January 2017 to July 2018. Data of 166 consecutive suspected extrapulmonary tuberculosis patients was retrieved. Effectiveness of CBNAAT in the diagnosis of EPTB was assessed as compared to that of AFB smear.Results: Samples collected from 166 suspected EPTB patients were subjected to AFB smear and CBNAAT. Samples collected included lymph node, pus, pleural fluid, tissue, CSF, gastric lavage, cystic fluid, peritoneal fluid, ascitic fluid, colonic fluid, synovial fluid, urine. In AFB smear results, 17 cases were positive for TB bacilli and 149 were negative for the same. In CBNAAT results, 25 cases were positive for TB bacilli and 141 cases were negative. In comparative analysis, 8 cases were AFB smear negative but CBNAAT positive.Conclusions: CBNAAT is a useful tool in the diagnosis of EPTB cases because of its simplicity and rapid turnaround time. CBNAAT is more effective as compared to AFB smear in the diagnosis of EPTB cases.
In the present study, a series of novel pyrido[1,2‐a]pyrimidin‐4‐one derivatives (1–45) were synthesized, characterized, and evaluated for their anti‐inflammatory activity. The structures of all newly synthesized compounds were confirmed by 1H NMR, 13C NMR, mass spectroscopy, and C, H, and N analyses. Preliminary these newly synthesized compounds were evaluated for their in vitro cyclooxygenase (COX)‐2/COX‐1 inhibitory activity. The celecoxib, a COX‐2 inhibitor, was used as a reference standard drug. In this inhibitory study, compounds 42, 43, 44, and 45 were found to have significant in vitro inhibitory profile as compared with the reference drug. These compounds were then subjected to their in vivo anti‐inflammatory assay by using carrageenan‐induced rat paw edema method in next level of screening. Later, these same compounds were tested for their ulcerogenic property. Based on these activity data, the compound 43 (in vitro COX‐2 activity—IC50 = 0.4 μM, SI = 400, in vivo anti‐inflammatory activity—72% inhibition after 3 h, and 0.38%—Ulcer index) was emerged as most promising anti‐inflammatory agent with very low ulcerogenic action.
A series of 20 novel pyrazole derivatives were designed and prepared, characterized by 1 H-NMR, mass spectra (ES-MS), 13 C-NMR, and elemental analysis. The synthesized compounds were then evaluated for their growth inhibitory activity against Mycobacterium smegmatis mc 2 155 initially. Rifampicin was used as standard reference. In this screening, derivatives 9, 10, and 11 presented superior inhibition compared with standard. Later, these three compounds were exposed for their Mycobacterium tuberculosis H37Rv inhibitory assay using rifampicin as standard reference. Encouraging M. smegmatis mc 2 155 inhibition (9 μg/ mL), M. tuberculosis H37Rv inhibition (1.9 μg/mL), and synergism with the first-line and second-line antibiotics made compound 10 as lead and safe antitubercular agent among the series.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.